Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Generate Biomedicines, Inc. - Common Stock (NQ:GENB)

13.57 -0.23 (-1.63%)
Delayed Quote Updated: 12:36 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Generate Biomedicines, Inc. - Common Stock

News headline image
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
From Generate Biomedicines, Inc.
Via GlobeNewswire
News headline image
Generate Biomedicines Inc. to Participate in September Investor Conferences
From Generate Biomedicines, Inc.
Via GlobeNewswire
News headline image
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
From Generate Biomedicines, Inc.
Via GlobeNewswire
News headline image
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It ↗
Generate Biomedicines focuses on AI-enabled drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? ↗
One small investment offers big benefits for Nvidia. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday ↗
Ark Invest's top investor is adding to stocks that went public over the past year. 
Via The Motley Fool
Topics ETFs Initial Public Offering
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example. 
Via MarketBeat
Topics Artificial Intelligence Economy Regulatory Compliance
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The growth investor kicked off this week by buying up some hard-hit stocks. 
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.